Literature DB >> 11779172

An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.

C Xu1, Y S Rao, B Xu, E Hoffmann, J Jones, E M Sellers, R F Tyndale.   

Abstract

We developed genotyping assays for CYP2A6*7 (Ile471Thr) and CYP2A6*8 (Arg485Leu). We found higher allelic frequencies in Japanese and Chinese versus Caucasians and identified an allele in which both substitutions occur together (CYP2A6*10). We created a homology model for predicting the impact of allelic variants on enzymatic activity and subsequently tested this in vivo in a pilot kinetic study. Consistent with our homology model predictions, we found (i) that CYP2A6*7 produces an enzyme that has decreased (not inactive) activity for metabolizing nicotine and coumarin; (ii) that CYP2A6*8 is unlikely to affect catalytic activity in vivo; and (iii) that having both substitutions together on an allele (CYP2A6*10) dramatically reduces function and may be fully inactive for some substrates. In conclusion, this study identifies, at relatively high frequency in Asians, an allele with decreased activity (may be substrate selective), a fully functional allele, and an allele containing both substitutions in which function is dramatically reduced. (c)2002 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779172     DOI: 10.1006/bbrc.2001.6209

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

2.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

3.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

4.  Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Authors:  Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2006-04-28       Impact factor: 2.953

5.  Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.

Authors:  Hiromi Tanii; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

6.  Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

7.  Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.

Authors:  Jill C Mwenifumbo; Edward M Sellers; Rachel F Tyndale
Journal:  Nicotine Tob Res       Date:  2008-08       Impact factor: 4.244

8.  Nicotine intake and smoking topography in smokers with bipolar disorder.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Bipolar Disord       Date:  2012-09       Impact factor: 6.744

9.  CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.

Authors:  Yu-liang Liu; Yu Xu; Fan Li; Hong Chen; Shu-liang Guo
Journal:  Tumour Biol       Date:  2013-05-07

10.  Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Authors:  Julie-Anne Tanner; Jeffrey A Henderson; Dedra Buchwald; Barbara V Howard; Patricia Nez Henderson; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.